CMND-100, a proprietary MEAI-based oral drug candidate, represents a potential breakthrough in AUD treatment, targeting the reduction of alcohol consumption and cravings through a novel mechanism of ...

Q4 2024 Earnings Call Transcript March 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx ...

Myers Squibb Company, Johnson & Johnson, Bausch Health Companies Inc, AbbVie Inc. Read 's Market Analysis on Investing.com ...

An international team led by UPV/EHU and Biobizkaia reveals the relationship between placental DNA methylation and certain ...

VA4PA advocates take their case for PANS/PANDAS treatment coverage to the General Assembly in Richmond, VA Law to take effect July 1 <b ...

Severe self-injurious behavior in children with autism spectrum disorder (ASD) poses a significant risk of permanent physical injury.

Severe self-injurious behavior in children with autism spectrum disorder (ASD) poses a significant risk of permanent physical ...

Of the 103 patients who completed the Phase III trial, more than half witnessed remission from a drug-induced condition that ...

A team of researchers from the Universitat Politècnica de València (UPV) and the French National Center for Scientific ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a collaboration LOI ...

US neuroscience-focused biopharma Neurocrine Biosciences (Nasdaq: NBIX) today presented new data from the long-term, ...

Discover an informative webinar featuring leading researchers as they discuss advancements in biomarker discovery for Alzheimer's disease (AD) and related dementias. This webinar will showcase how the ...